NCT00331175已完成1 期
A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Food intake
研究概览
简要总结
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •BMI 27-35 kg/m2
排除标准
- •Women of childbearing potential
结局指标
主要结局
Food intake
次要结局
- Plasma biomarkers, safety, toleration
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy ParticipantsHealthyNCT05501717Alexion Pharmaceuticals, Inc.48
已完成
1 期
A Study to Evaluate ALN-AGT01 RVR in Adult Healthy VolunteersHealthy VolunteersNCT06675565Alnylam Pharmaceuticals42
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsHealthy VolunteersNCT06193031Insmed Incorporated24
已完成
1 期
A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic DermatitisAtopic DermatitisNCT04643457UCB Biopharma SRL107
已完成
1 期
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)Atopic DermatitisNCT05277571UCB Biopharma SRL109